Scholar Rock Holding Corporation (SRRK)

Fisher Asset Management LLC lowered its position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 9.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 412,411 shares of the company's stock after selling 44,460 shares during the period. Fisher Asset Management LLC owned 0.43%

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP's 13F reportable assets under management.

Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director R. Keith Woods Vikas Sinha - Chief Financial Officer Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Kripa Devarakonda Etzer Darout - Barclays Bank PLC, Research Division Marc Frahm - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Presentation Operator Good morning, ladies and gentlemen, and welcome to Scholar Rock's Third Quarter 2025 Conference Call.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. “W.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857 shares of its common stock. The awards are subject to all terms and conditions and other provisions s.

Earnings season often shines a spotlight on well-known mega-caps, but it can also bring opportunities for lesser-known companies to shine. Below are three stocks—each down significantly in 2025—that could stage a comeback if their upcoming earnings updates hit the right notes.

Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release of the financials, the Company will host a live audio webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To p.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the company granted inducement equity awards covering an aggregate of 114,500 shares of its common st.

The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.

A potential delay in an important submission was the news item driving Scholar Rock's (SRRK -13.14%) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more than 13% as a result, contrasting unfavorably with the 1.6% gain of the S&P 500 (^GSPC 1.56%).

An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (SRRK 5.95%) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on a trading day when the benchmark S&P 500 (^GSPC -0.28%) sagged by 0.3%.

People don't like to throw money into a sinking ship , and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do in the coming quarters.

Scholar Rock Holding Corporation remains a Strong Buy despite a recent FDA Complete Response Letter for apitegromab in spinal muscular atrophy. The CRL was due to manufacturing site issues with Catalent Indiana LLC, not safety or efficacy, and a quick BLA resubmission is expected once resolved. Company has catalysts ahead, including EMA review for apitegromab in mid-2026 and promising phase 2 data in obesity showing preserved lean muscle mass.

The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA).